DUBLIN--(BUSINESS WIRE)--The "Cholbam 2017 U.S. Promotional Audit Report" report has been added to ResearchAndMarkets.com's offering.
The 5 Key Questions Addressed by this Report:
- How many physicians were reached by Cholbam through reportable promotional activity in 2017 to drive use within the Bile Acid Synthesis Disorders, Peroxisomal Disorders, and Zellweger Syndrome markets?
- What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend for each type of activity?
- How does Retrophin's depth of coverage vary within key specialties (e.g., Pediatric Medicine, Neurology, Medical Genetics, and Gastroenterology) and how does this compare to the overall set of rep-accessible physicians?
- How often are physicians receiving paid meals for Cholbam throughout the year (e.g., monthly, quarterly, annually)?
- Who were the most frequent meal recipients and top paid speakers for Cholbam in 2017?
Data Sources and Methodology:
- The author leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. More than four years of longitudinal data is available - covering payments to more than 975,000 U.S. healthcare professionals.
- Over 1,600 paid interactions across 100 physicians made on behalf of Cholbam were carefully examined to support our analysis.
For more information about this report visit https://www.researchandmarkets.com/research/shmhzk/cholbam_2017_u_s?w=4
